Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN1 | O60741 | 1/20 | 0.41 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320240 | 0.88 | MEN1 (0.43) | HCN1HCN4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11465103 | 0.81 | NOTUM (0.40) | HCN1HCN4SMN1; SMN2ATM | |
| SCHEMBL11431593 | 0.81 | NOTUM (0.40) | HCN1HCN4SMN1; SMN2ATM | |
| SCHEMBL11411488 | 0.79 | CXCR5 (0.40) | ATMHDAC9 | |
| SCHEMBL29156256 | 0.79 | TACR1 (0.39) | HCN1HCN4TACR1TACR3MEN1 | |
| SCHEMBL12203624 | 0.79 | TACR1 (0.39) | HCN1HCN4TACR1TACR3MEN1 | |
| SCHEMBL15221428 | 0.78 | GHSR (0.41) | HCN1HCN4TACR1TACR3MEN1 | |
| SCHEMBL9527330 | 0.76 | TACR1 (0.40) | HCN1HCN4TACR1TACR3SMN1; SMN2 | |
| SCHEMBL28260472 | 0.75 | SMN1; SMN2 (0.36) | HCN1HCN4TACR1TACR3MEN1 | |
| SCHEMBL13435777 | 0.75 | CXCR5 (0.42) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066378-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12162887-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230106150-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11578077-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578077-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200039997-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-3083633-A1 | SPIRO-OXAZOLONES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091411-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091411-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162887-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
| US-11578077-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
| US-20250066378-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
| US-20200039997-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
| US-20170008901-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
| US-20230106150-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
| US-10479796-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | HCN1 1072/4885HCN4 2090/4885TACR1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.